Test Article

Allegheny Health Network announced the initiation of a Phase 1/2 study to assess the safety and efficacy of azeliragon in patients refractory to first-line treatment of metastatic pancreatic cancer.

Matthew Hadfield, DO, discusses his passion for early-stage clinical trials and the need for more research into immunotherapy toxicities during the third episode of Emerging Experts.

In an interview with Peers & Perspectives in Oncology, Teresa L. Deshields, PhD, ABPP, discussed how oncologists can guide patients with cancer to mental health resources.

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Results from an international phase 2 study show that using metronomic capecitabine in combination with the tyrosine kinase inhibitor pyrotinib continued to have promising efficacy results for patients with HER2-positive metastatic breast cancer.

A phase 1 trial plans to be initiated in 2024 to investigate GTB-3650 for the treatment of patients with CD33-positive leukemia.